NCT00271466View on ClinicalTrials.gov

A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

February 29, 2000

Study Completion Date

April 30, 2002

Conditions
Chronic Pain
Interventions
DRUG

Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00271466 - A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy | Biotech Hunter | Biotech Hunter